medigraphic.com
ISSN 1561-2988 (Print)

2015, Number 1

<< Back Next >>

Rev Cubana Farm 2015; 49 (1)

Detection of adverse reactions to Cytochrome P4502C9- metabolized drugs

Álvarez CM, Cervelo FY, Pérez HB, González HOJ

Language: Spanish
References: 20
Page: 38-46
PDF size: 86.00 Kb.


ABSTRACT

Introduction: the existence of variations in the drug response among individuals is multifactoral and includes genetics and environment; so it is important for clinical practice to consider the effects of drugs that are biologically transformed by polymorphic enzymes such as cytochrome P4502C9 (CYP2C9), which roughly metabolizes 16% of regularly used drugs so that the association of pharmacovigilance and pharmacogenetic studies would allow relating some drugs with possibilities of adverse reactions, and therefore, being more rational in drug therapy.
Objective: to describe the occurrence of adverse reactions to drugs metabolized by CYP2C9 in patients from a physician's office.
Methods: observational, descriptive and cross-sectional study conducted in 143 patients from a physician's office of "Joaquin Albarran" polyclinics, who took CYP2C9-metabolized drugs in the study period.
Results: there were detected 43 adverse reactions, being 88.4% of them linked to non-steroidal anti-inflammatory drugs; Ibuprofen accounted for 65.1% of them. Age and sex did not influence the occurrence of reactions. In the group;, 55.8% of reactions were rated as mild.
Conclusions: the fifth part of patients who showed adverse reactions had taken cytochrome CYP2C9-metabolized drugs, they were not sufficient to predict response to traditionally accepted variable drugs as well as age and sex. The factors having an impact on the capacity of biotransformation of drug-metabolizing enzymes should be taken into consideration at the time of prescription of a drug.


REFERENCES

  1. Cavallari LH. Tailoring Drug Therapy Based on Genotype. J Pharm Pract. 2012;25(4):413-6.

  2. Kudzi W, Adjei GO, Ofori-Adjei D, Dodoo AN. Pharmacogenetics in Ghana: reviewing the evidence. Ghana Med J. 2011;45(2):73-80.

  3. Wang D, Jiang Z, Shen Z, Wang H, Wang B, Shou W, et al. Functional evaluation of genetic and environmental regulators of p450 mRNA levels. PLoS One. 2011;6(10):e24900. Epub. 2011; Oct 5.

  4. Josansson I, Ingelman-Sundberg M. Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450. [on line]. 2011 [citado 31 agosto 2012]; [aprox 13p]. Disponible en: http://toxsci.oxfordjournals.org/content/120/1/1.long

  5. Chile Orellana R. Pharmacological surveillance system in the Hospital of the University of Chile. Medwave. 2011;11(08):e5111 DOI: 10.5867/medwave.2011.08.5111.

  6. Calderón CA, Urbina AP. La Farmacovigilancia en los últimos 10 años: actualización de conceptos y clasificaciones. Logros y retos para el futuro en Colombia. MéD.UIS. 2010;24:57-73.

  7. Pardo Cabello AJ. Reacciones adversas medicamentosas fatales en pacientes hospitalizados [tesis doctoral]. Granada: Universidad de Granada, Facultad de Medicina; 2008.

  8. Milián García AJ. Caracterización epidemiológica del consumo de medicamentos por la población adulta de Cuba. 2007-2010 [tesis doctoral]. La Habana: Escuela Nacional de Salud Pública; 2010.

  9. Dorado P, Álvarez M, Pérez B, Llerena A. Comportamiento de la relación genotipo-fenotipo del citocromo CYP2C9 en una muestra de cubanos. Rev Cub Farm 2007; 41(Supl Esp 2):259-260.

  10. Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arq Neuropsiquiatr. 2011;69(2A):153-8.

  11. Grice GR, Seaton TL, Woodland AM, McLeod HL. Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics. 2006; 7(1):61-5.

  12. Centro para el Desarrollo de la Farmacoepidemiologia. Unidad Coordinadora Nacional de Farmacovigilancia Informe Anual 2009 [citado 18 Mayo 2011]; Disponible en: http://files.sld.cu/cdfc/files/2010/02/informe-anual-2009.pdf.

  13. Centro para el Desarrollo de la Farmacoepidemiologia. Unidad Coordinadora Nacional de Farmacovigilancia. Informe Anual 2010 [citado 18 Mayo 2011]. Disponible en: http://files.sld.cu/cdfc/files/2010/02/informe-anual-2010.pdf.

  14. Sarkar U, López A, Maselli JH, González R. Adverse drug events in U.S. adult ambulatory medical care. Health Serv Res. 2011;46(5):1517-33.

  15. Pirmohamed M, Park K. Adverse drug reactions: back to the future. Br J Clin Pharmacol. 2003;55(5):486–492.

  16. Rascón-Sabido R, Sabido-Siglher AS, Márquez-Celedonio FG, Soler-Huerta E. Programa de Farmacovigilancia en atención primaria: experiencia en una clínica de Veracruz, México. Archivos en Medicina Familiar [Revista on-line]. 2007 [citado 12 Julio 2011]; 9(2): [aprox 10p.]. Disponible en: http://redalyc.uaemex.mx/src/inicio/ArtPdfRed.jsp?iCve=50711454005.

  17. Jiménez G, Lara M, Bayarre H, Rego J, García B. Costo de los efectos adversos que causan ingreso en hospitales seleccionados de Ciudad de La Habana. Año 2006. Boletín Fármacos [Revista on-line]. 2009 [citado 20 Mayo 2011]; 12(2): [aprox 6p.]. Disponible en: www.boletinfarmacos.org/.../advertencias_sobre_ medicamentos_Investigaciones.asp .

  18. Chao A, Díaz I, Jiménez G, López Y, Fernández X. Análisis de las sospechas de reacciones adversas producidas por analgésicos no opioide. Boletín Fármacos [Revista on-line]. 2009 [citado 20 Mayo 2011]; 12(2): [aprox 8p.]. Disponible en: http://www.boletinfarmacos.org/042009/advertencias_sobre_medicamentos_Invest igaciones.asp .

  19. Zavaleta M, Rosete A. Reacciones adversas a medicamentos (RAM) en el Hospital Médica Sur. Avances y dirección de nuestros logros. Rev Médica Sur, México [Revista on-line]. 2007 [citado 12 diciembre 2010]; 14(4): [aprox 8p.]. Disponible en: http://www.medigraphic.com/pdfs/medsur/ms-2007/ms074b.pdf .

  20. Tribiño G, Maldonado C, Segura O, Díaz J. Costos directos y aspectos clínicos de las reacciones adversas a medicamentos en pacientes hospitalizados en el servicio de medicina interna de una institución de tercer nivel en Bogotá. Biomédica [Revista on-line]. 2006 [citado 28 Mayo 2011]; 26 (001): [aprox 11p.]. Disponible en: http://redalyc.uaemex.mx/redalyc/src/inicio/ArtPdfRed.jsp?iCve.




2020     |     www.medigraphic.com